Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.